Marloes E C Broekmans
Overview
Explore the profile of Marloes E C Broekmans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkleij C, ONeill C, Broekmans M, Frerichs K, Bruins W, Duetz C, et al.
Clin Cancer Res
. 2024 Apr;
30(14):3006-3022.
PMID: 38687588
Purpose: Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma....
2.
Verkleij C, Frerichs K, Broekmans M, Duetz C, ONeill C, Bruins W, et al.
Hemasphere
. 2023 May;
7(5):e881.
PMID: 37153876
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII...
3.
Verkleij C, Broekmans M, van Duin M, Frerichs K, Kuiper R, de Jonge A, et al.
Blood Adv
. 2021 Apr;
5(8):2196-2215.
PMID: 33890981
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders...
4.
Verkleij C, Jhatakia A, Broekmans M, Frerichs K, Zweegman S, Mutis T, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33321969
The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38 regulatory T-cells, regulatory B-cells,...
5.
Frerichs K, Broekmans M, Marin Soto J, van Kessel B, Heymans M, Holthof L, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2203-2215.
PMID: 31969333
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of action. Experimental Design: We...
6.
Krejcik J, Frerichs K, Nijhof I, van Kessel B, van Velzen J, Bloem A, et al.
Clin Cancer Res
. 2017 Oct;
23(24):7498-7511.
PMID: 29025767
Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of...
7.
Valentijn L, Koster J, Haneveld F, Aissa R, van Sluis P, Broekmans M, et al.
Proc Natl Acad Sci U S A
. 2012 Oct;
109(47):19190-5.
PMID: 23091029
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor...
8.
van der Loos C, Meijer-Jorna L, Broekmans M, Ploegmakers H, Teeling P, de Boer O, et al.
J Histochem Cytochem
. 2009 Sep;
58(2):109-18.
PMID: 19786611
Nine commercially available vascular endothelial growth factor (VEGF) antibodies were investigated for their ability to immunostain vascular malformations (VMs) with or without immature capillary proliferation. First, all antibodies were optimized...